Stay updated on IMO-2125 Combo With Ipilimumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the IMO-2125 Combo With Ipilimumab in Melanoma Clinical Trial page.

Latest updates to the IMO-2125 Combo With Ipilimumab in Melanoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe page has undergone significant content removal regarding the details of a Phase 1/2 study for metastatic melanoma, including specific inclusion and exclusion criteria, as well as the study's goals and design. The only notable addition is the mention of 'Metastatic Melanoma' and a new revision number.SummaryDifference31%
- Check34 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check77 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check92 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check99 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
Stay in the know with updates to IMO-2125 Combo With Ipilimumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IMO-2125 Combo With Ipilimumab in Melanoma Clinical Trial page.